In a large population of people with diabetes, the use of GLP-1 receptor agonists was not linked to an increased risk for ...

While weight loss is a common new year's resolution for workers in the U.S., 2025 may mark the year that building weight loss ...

The series A fundraising is the biggest ever for a European biotech firm, according to the data provider PitchBook.

Lexaria Bioscience (LEXX) announces partial final results showcasing the tolerability and glycemic control efficacy findings from human study ...

The most negatively impacted sectors are frozen, refrigerated, general food and beverages. Circana found GLP-1 users’ monthly ...

Cancer researchers found that patients on GLP-1s had significant risk reductions for 10 of 13 obesity-associated cancers.

For patients with diabetes undergoing a surgical procedure, an active perioperative glucagon-like peptide-1 receptor agonist ...

A dozen GLP-1 receptor agonists and coagonists demonstrated effectiveness for weight loss in adults with obesity and without ...

Most people have missed a dose of prescription medication at some point. But if you are taking a glucagon-like peptide-1 drug ...

Scientists have found a way to help the body make more of an Ozempic-like fullness hormone to cut cravings and improve health.

In previous First Word columns, I discussed the effects of SGLT2 inhibitors on the kidney to prevent progression of chronic ...

A study has found no evidence that glucagon-like peptide 1 receptor agonist (GLP1-RA) use is associated with an increased ...